Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
sorafenib
i
Other names:
BAY 43-9006, BAY 439006, BAY43-9006, BAY 54-9085, BAY-43-9006
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(180)
News
Trials
Company:
Generic mfg.
Drug class:
Multi-tyrosine kinase inhibitor, pan-RAF inhibitor
Related drugs:
‹
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
LY3009120 (22)
RG6185 (19)
BGB-283 (12)
AZ 628 (9)
tovorafenib (9)
ERAS-254 (7)
PHI-501 (5)
BAL3833 (4)
KIN-2787 (4)
TAK‐632 (3)
CCT241161 (2)
JZP815 (2)
SJ-C1044 (2)
BGB659 (1)
CCT196969 (1)
DCC-3084 (0)
XP-102 (0)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
LY3009120 (22)
RG6185 (19)
BGB-283 (12)
AZ 628 (9)
tovorafenib (9)
ERAS-254 (7)
PHI-501 (5)
BAL3833 (4)
KIN-2787 (4)
TAK‐632 (3)
CCT241161 (2)
JZP815 (2)
SJ-C1044 (2)
BGB659 (1)
CCT196969 (1)
DCC-3084 (0)
XP-102 (0)
›
Associations
(180)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Chordoma
No biomarker
Chordoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Sarcoma
No biomarker
Sarcoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
BRAF fusion
Melanoma
BRAF fusion
Melanoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
sorafenib + everolimus
Sensitive: A2 - Guideline
sorafenib + everolimus
Sensitive
:
A2
sorafenib + everolimus
Sensitive: A2 - Guideline
sorafenib + everolimus
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
sorafenib
Resistant: A2 - Guideline
sorafenib
Resistant
:
A2
sorafenib
Resistant: A2 - Guideline
sorafenib
Resistant
:
A2
No biomarker
Kidney Cancer
No biomarker
Kidney Cancer
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
RAF1 amplification
Melanoma
RAF1 amplification
Melanoma
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
KRAS amplification
Melanoma
KRAS amplification
Melanoma
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
CCND1 amplification
Melanoma
CCND1 amplification
Melanoma
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
sorafenib
Sensitive: B - Late Trials
sorafenib
Sensitive
:
B
HGF elevation + VEGFA elevation
Hepatocellular Cancer
HGF elevation + VEGFA elevation
Hepatocellular Cancer
erlotinib + sorafenib
Resistant: B - Late Trials
erlotinib + sorafenib
Resistant
:
B
erlotinib + sorafenib
Resistant: B - Late Trials
erlotinib + sorafenib
Resistant
:
B
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
sorafenib + LY2157299
Sensitive: C2 – Inclusion Criteria
sorafenib + LY2157299
Sensitive
:
C2
sorafenib + LY2157299
Sensitive: C2 – Inclusion Criteria
sorafenib + LY2157299
Sensitive
:
C2
AFP elevation
Hepatocellular Cancer
AFP elevation
Hepatocellular Cancer
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
sorafenib
Sensitive: C2 – Inclusion Criteria
sorafenib
Sensitive
:
C2
FLT3 D835H
Acute Myelogenous Leukemia
FLT3 D835H
Acute Myelogenous Leukemia
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
KIAA1549-BRAF fusion
Soft Tissue Sarcoma
KIAA1549-BRAF fusion
Soft Tissue Sarcoma
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C3
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
bevacizumab + sorafenib + temsirolimus
Sensitive
:
C3
PBRM1 underexpression
Renal Cell Carcinoma
PBRM1 underexpression
Renal Cell Carcinoma
sorafenib
Resistant: C3 – Early Trials
sorafenib
Resistant
:
C3
sorafenib
Resistant: C3 – Early Trials
sorafenib
Resistant
:
C3
PBRM1 overexpression
Renal Cell Carcinoma
PBRM1 overexpression
Renal Cell Carcinoma
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
FOXA3 overexpression
Hepatocellular Cancer
FOXA3 overexpression
Hepatocellular Cancer
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
sorafenib
Sensitive: C3 – Early Trials
sorafenib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login